{"nctId":"NCT02425891","briefTitle":"A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)","startDateStruct":{"date":"2015-06-23","type":"ACTUAL"},"conditions":["Triple Negative Breast Cancer"],"count":902,"armGroups":[{"label":"Atezolizumab Plus Nab-Paclitaxel","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody","Drug: Nab-Paclitaxel"]},{"label":"Placebo Plus Nab-Paclitaxel","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Nab-Paclitaxel","Drug: Placebo"]}],"interventions":[{"name":"Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody","otherNames":["Tecentriq, MPDL3280A"]},{"name":"Nab-Paclitaxel","otherNames":["AbraxaneÂ®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Metastatic or locally advanced, histologically documented TNBC characterized by absence of human epidermal growth factor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression\n* No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC\n* Eligible for taxane monotherapy (i.e., absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control)\n* A representative formalin-fixed, paraffin-embedded tumor specimen in paraffin blocks, or at least 20 unstained slides with an associated pathology report documenting ER, PR, and HER2 negativity. Participants with fewer than 20 unstained slides available at baseline, and not fewer than 12 unstained slides will be eligible upon discussion with Medical Monitor\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Measurable disease as defined by RECIST v1.1\n* Adequate hematologic and end-organ function\n\nExclusion Criteria:\n\n* Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases\n* Leptomeningeal disease\n* Pregnancy or lactation\n* History of autoimmune disease\n* Prior allogeneic stem cell or solid organ transplantation\n* Positive test for human immunodeficiency virus\n* Active hepatitis B or hepatitis C\n* Receipt of a live, attenuated vaccine within 4 weeks prior to randomization, during treatment, or within 5 months following the last dose of atezolizumab/placebo","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants","description":"PFS was defined as the time from randomization to the occurrence of disease progression, as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause, whichever occurred first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.49","spread":null},{"groupId":"OG001","value":"7.16","spread":null}]}]}]},{"type":"PRIMARY","title":"PFS According to RECIST v1.1 in Participants With Detectable Programmed Death-Ligand 1 (PD-L1)","description":"PFS was defined as the time from randomization to the occurrence of disease progression, as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause, whichever occurred first.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.96","spread":null},{"groupId":"OG001","value":"7.46","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS) in All Randomized Participants","description":"OS was defined as the time from the date of randomization to the date of death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.73","spread":null},{"groupId":"OG001","value":"21.03","spread":null}]}]}]},{"type":"PRIMARY","title":"OS in Participants With Detectable PD-L1","description":"OS was defined as the time from the date of randomization to the date of death from any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.91","spread":null},{"groupId":"OG001","value":"25.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 in All Randomized Participants","description":"An objective response was defined for participants with measurable disease at baseline as either a partial response (PR) or a complete response (CR) using RECIST v1.1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":null},{"groupId":"OG001","value":"56.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Objective Response of CR or PR According to RECIST v1.1 in Participants With Detectable PD-L1","description":"An objective response was defined for participants with measurable disease at baseline as either a partial response (PR) or a complete response (CR) using RECIST v1.1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":null},{"groupId":"OG001","value":"58.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) According to RECIST v1.1 in All Randomized Participants","description":"DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause, whichever occurred first.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.62","spread":null},{"groupId":"OG001","value":"7.39","spread":null}]}]}]},{"type":"SECONDARY","title":"DOR Acccording to RECIST v1.1 in Participants With Detectable PD-L1","description":"DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause, whichever occurred first.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.49","spread":null},{"groupId":"OG001","value":"8.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration (TTD) in Global Health Status/Health Related Quality of Life According to European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) v3.0 in All Randomized Participants","description":"Deterioration in GHS/HRQoL (Items 29, 30 of the EORTC QLQ C30) was defined by the following two criteria: 1. The time from randomization to the first time the participant's GHS/HRQoL scale score showed a \\>=10-point decrease from the baseline scale score. A 10-point change was defined as the minimally important difference (MID). 2. The score decrease of \\>= 10-points from baseline was held for at least two consecutive cycles, or an initial score decrease of \\>= 10-points was followed by death or treatment discontinuation within 3 weeks from the last assessment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.98","spread":null},{"groupId":"OG001","value":"8.18","spread":null}]}]}]},{"type":"SECONDARY","title":"TTD in Global Health Status/Health Related Quality of Life According to EORTC QLQ-C30 v3.0 in Participants With Detectable PD-L1","description":"Deterioration in GHS/HRQoL (Items 29, 30 of the EORTC QLQ C30) was defined by the following two criteria: 1. The time from randomization to the first time the participants's GHS/HRQoL scale score showed a \\>=10-point decrease from the baseline scale score. A 10-point change was defined as the minimally important difference (MID). 2. The score decrease of \\>= 10-points from baseline was held for at least two consecutive cycles, or an initial score decrease of \\>= 10-points was followed by death or treatment discontinuation within 3 weeks from the last assessment.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.41","spread":null},{"groupId":"OG001","value":"7.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least One Adverse Event","description":"Percentage of participants with at least one adverse event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab","description":"Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Serum Concentration (Cmax) for Atezolizumab","description":"Maximum serum concentration for atezolizumab.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"329","spread":"98.9"}]}]}]},{"type":"SECONDARY","title":"Minimum Serum Concentration (Cmin) for Atezolizumab","description":"Minimum serum concentration for atezolizumab.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":"52.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":"78.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":"90.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"274","spread":"111"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentrations of Total Paclitaxel","description":"Plasma Concentrations of Total Paclitaxel","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2970","spread":"2300"},{"groupId":"OG001","value":"3080","spread":"2050"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"370","spread":"244"},{"groupId":"OG001","value":"400","spread":"275"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":80,"n":430},"commonTop":["ALOPECIA","FATIGUE","NAUSEA","DIARRHOEA","ANAEMIA"]}}}